Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

SUCAMPO PHARMACEUTICALS, INC. (SCMP)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesNewsAnalysisCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Latest news on SUCAMPO PHARMACEUTICALS, I
02/15MALLINCKRODT : Completes Acquisition Of Sucampo Pharmaceuticals, Inc.
AQ
01/25MONTEVERDE & ASSOCIATES PC : Files Class Action Lawsuit On Behalf Of Shareholder..
PR
01/22SUCAMPO PHARMACEUTICALS : SCMP) Andrews & Springer LLC Is Investigating Sucampo..
BU
01/11SUCAMPO PHARMACEUTICALS : Wolf Popper LLP Investigates the Proposed Acquisition ..
AQ
01/04MALLINCKRODT : To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
AQ
01/03Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whethe..
BU
01/02SUCAMPO PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
01/01Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceutic..
PR
2017SUCAMPO PHARMACEUTICALS, INC. Former SEC Attorney Willie Briscoe Investigates..
BU
2017MALLINCKRODT : to Acquire Sucampo Pharmaceuticals for Approximately $1.2 Billion
AQ
2017SUCAMPO PHARMACEUTICALS, INC. : SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announ..
AC
2017CORRECTING AND REPLACING INVESTOR AL : Levi & Korsinsky, LLP Notifies Investors ..
BU
2017SUCAMPO PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation ..
BU
2017SUCAMPO PHARMACEUTICALS, INC. : Brodsky & Smith, LLC Announces an Investigation ..
AC
2017SUCAMPO PHARMACEUTICALS : Mallinckrodt makes gains
AQ
2017RATING ACTION : Moody's places Mallinckrodt's ratings under review for downgrade..
AQ
2017MALLINCKRODT : BioCentury - Mallinckrodt acquiring Sucampo
AQ
2017SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Entry into a Material ..
AQ
2017Kohl's and Sucampo climb while Apple and Qorvo stumble
AQ
2017SUCAMPO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Chan..
AQ
2017MALLINCKRODT : to buy Sucampo for about $840 million
RE
2017Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Inve..
GL
2017SUCAMPO PHARMACEUTICALS : Cancer Prevention Pharmaceuticals to Present at the 29..
AQ
2017SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 29th Annu..
AQ
2017Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Ann..
GL
2017SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
AQ
2017Sucampo to Host 2017 R&D Day on November 16 in New York
GL
2017SUCAMPO PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results
AQ
2017SUCAMPO PHARMACEUTICALS : Results of Operations and Financial Condition, Financi..
AQ
2017SUCAMPO PHARMACEUTICALS, INC. : Class A to Host Earnings Call
AC
2017SUCAMPO PHARMACEUTICALS : tops 3Q revenue forecasts
AQ
2017SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
2017SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
AQ
2017Sucampo Reports Third Quarter 2017 Financial Results
GL
2017SUCAMPO PHARMACEUTICALS : Announces Third Quarter 2017 Earnings Call
AQ
2017SUCAMPO PHARMACEUTICALS : Submission of Matters to a Vote of Security Holders (f..
AQ
2017Sucampo Announces Third Quarter 2017 Earnings Call
GL
2017SUCAMPO PHARMACEUTICALS : Announces FDA Acceptance of sNDA for AMITIZA in Childr..
AQ
2017SUCAMPO PHARMACEUTICALS : Announces Presentation at Deutsche Bank's 25th Annual ..
AQ
2017Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Child..
GL
2017Sucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th ..
GL
2017SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
AQ
2017SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 2017
AQ
2017SUCAMPO PHARMACEUTICALS ANNOUNCES WE : Rare Disease & Immuno-Oncology
AQ
2017CANCER PREVENTION PHARMACEUTICALS : Receives $9.5 Million in Additional Funding ..
AQ
2017SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 2017 Cant..
AQ
2017SUCAMPO PHARMACEUTICALS ANNOUNCES WE : Rare Disease & Immuno-Oncology
GL
2017SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Finan..
AQ
2017Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel
GL
2017SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 2017 Cant..
AQ
2017SUCAMPO PHARMACEUTICALS : Cancer Prevention Pharmaceuticals Receives $9.5 Millio..
AQ
2017SUCAMPO PHARMACEUTICALS : Cancer Prevention Pharmaceuticals Receives $9.5 Millio..
BU
2017SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Entry into a Material ..
AQ
2017SUCAMPO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form..
AQ
2017Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Wel..
GL
2017SUCAMPO PHARMACEUTICALS : Study Results Published in The Lancet Demonstrate Safe..
PU
2017SUCAMPO PHARMACEUTICALS : Drug Makers Stock Performance Review -- DURECT, Sucamp..
PR
2017SUCAMPO PHARMACEUTICALS : reports 2Q loss
AQ
2017SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
2017SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
AQ
2017SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Results of Operations ..
AQ
2017Sucampo Reports Second Quarter 2017 Financial Results
GL
2017SUCAMPO PHARMACEUTICALS, INC. : Investor Network: Sucampo Pharmaceuticals, Inc. ..
AC
2017SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Departure of Directors..
AQ
2017SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regul..
AQ
2017Sucampo Announces Second Quarter 2017 Earnings Call
GL
2017Dr. Karen Smith Joins Sucampo’s Board of Directors
GL
2017Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
GL
2017Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferie..
GL
2017SUCAMPO PHARMACEUTICALS : Technical Reports on Drug Makers Stocks -- Synergy Pha..
PR
2017Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of ..
GL
2017SUCAMPO PHARMACEUTICALS, INC. : Investor Network: Sucampo Pharmaceuticals, Inc. ..
AC
2017Sucampo Reports First Quarter 2017 Financial Results
GL
2017Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche..
GL
2017Sucampo Announces First Quarter 2017 Earnings Call
GL
1  2  3  4Next
Managers
NameTitle
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Maureen E. O'Connell Independent Director
Robert Jay Spiegel Independent Director
Paul R. Edick Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICALS, INC.0.28%0
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 467
NEUROCRINE BIOSCIENCES, INC.32.61%9 250